Publicaciones en las que colabora con Elena Baixeras Llano (27)

2023

  1. Administration of Linoleoylethanolamide Reduced Weight Gain, Dyslipidemia, and Inflammation Associated with High-Fat-Diet-Induced Obesity

    Nutrients, Vol. 15, Núm. 20

2022

  1. Discovery of V-0219: A Small-Molecule Positive Allosteric Modulator of the Glucagon-Like Peptide-1 Receptor toward Oral Treatment for "diabesity"

    Journal of Medicinal Chemistry, Vol. 65, Núm. 7, pp. 5449-5461

  2. Endocrine and Metabolic Impact of Oral Ingestion of a Carob-Pod-Derived Natural-Syrup-Containing D-Pinitol: Potential Use as a Novel Sweetener in Diabetes

    Pharmaceutics, Vol. 14, Núm. 8

  3. d-Pinitol promotes tau dephosphorylation through a cyclin-dependent kinase 5 regulation mechanism: A new potential approach for tauopathies?

    British Journal of Pharmacology, Vol. 179, Núm. 19, pp. 4655-4672

2021

  1. Activation of pi3k/akt signaling pathway in rat hypothalamus induced by an acute oral administration of d-pinitol

    Nutrients, Vol. 13, Núm. 7

  2. Palmitoleoylethanolamide is an efficient anti-obesity endogenous compound: Comparison with oleylethanolamide in diet-induced obesity

    Nutrients, Vol. 13, Núm. 8

2020

  1. Cocaine-induced changes in CX3CL1 and inflammatory signaling pathways in the hippocampus: Association with IL1β

    Neuropharmacology, Vol. 162

  2. D-chiro-inositol treatment affects oocyte and embryo quality and improves glucose intolerance in both aged mice and mouse models of polycystic ovarian syndrome

    International Journal of Molecular Sciences, Vol. 21, Núm. 17, pp. 1-19

  3. D-pinitol from ceratonia siliqua is an orally active natural inositol that reduces pancreas insulin secretion and increases circulating ghrelin levels in wistar rats

    Nutrients, Vol. 12, Núm. 7, pp. 1-22

  4. Peroxisome Proliferator-Activated Receptors: Experimental Targeting for the Treatment of Inflammatory Bowel Diseases

    Frontiers in Pharmacology, Vol. 11

2018

  1. The adiponectin promoter activator NP-1 induces high levels of circulating TNFα and weight loss in obese (fa/fa) Zucker rats

    Scientific Reports, Vol. 8, Núm. 1

2016

  1. Chronic IL-6 administration desensitizes IL-6 response in liver, causes hyperleptinemia and aggravates steatosis in diet-induced-obese mice

    PLoS ONE, Vol. 11, Núm. 6

  2. Role of the satiety factor oleoylethanolamide in alcoholism

    Addiction Biology, Vol. 21, Núm. 4, pp. 859-872

  3. Single administration of recombinant IL-6 restores the gene expression of lipogenic enzymes in liver of fasting IL-6-deficient mice

    British Journal of Pharmacology, Vol. 173, Núm. 6, pp. 1070-1084

2015

  1. Chronic administration of recombinant IL-6 upregulates lipogenic enzyme expression and aggravates high-fat-diet-induced steatosis in IL-6-deficient mice

    DMM Disease Models and Mechanisms, Vol. 8, Núm. 7, pp. 721-731

  2. Pharmacological blockade of cannabinoid CB1 receptors in diet-induced obesity regulates mitochondrial dihydrolipoamide dehydrogenase in muscle

    PLoS ONE, Vol. 10, Núm. 12

  3. Plasma profile of pro-inflammatory cytokines and chemokines in cocaine users under outpatient treatment: Influence of cocaine symptom severity and psychiatric co-morbidity

    Addiction Biology, Vol. 20, Núm. 4, pp. 756-772

  4. Treatment with a novel oleic-acid-dihydroxyamphetamine conjugation ameliorates non-alcoholic fatty liver disease in obese Zucker rats

    DMM Disease Models and Mechanisms, Vol. 8, Núm. 10, pp. 1213-1225

2014

  1. CB1 blockade potentiates down-regulation of lipogenic gene expression in perirenal adipose tissue in high carbohydrate diet-induced obesity

    PLoS ONE, Vol. 9, Núm. 2

  2. Oleoylethanolamide enhances β-adrenergic-mediated thermogenesis and white-to-brown adipocyte phenotype in epididymal white adipose tissue in rat

    DMM Disease Models and Mechanisms, Vol. 7, Núm. 1, pp. 129-141